v3.26.1
Revenue
 6 Months Ended
Jun. 30, 2026
Revenue from Contract with Customer [Abstract]  
Revenue
Note 3 — Revenue

Abbott’s revenues are derived primarily from the sale of a broad portfolio of healthcare products under short-term receivable arrangements. Abbott has four reportable segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Medical Devices.

The following tables provide detail by sales category:

Three Months Ended June 30, 2026Three Months Ended June 30, 2025
(in millions)U.S.Int’lTotalU.S.Int’lTotal
Established Pharmaceutical Products —
Key Emerging Markets$— $1,164 $1,164 $— $1,059 $1,059 
Other— 335 335 — 324 324 
Total— 1,499 1,499 — 1,383 1,383 
Nutritional Products —    
Pediatric Nutritionals525 500 1,025 587 467 1,054 
Adult Nutritionals346 773 1,119 370 788 1,158 
Total871 1,273 2,144 957 1,255 2,212 
Diagnostic Products —     
Core Laboratory377 1,041 1,418 351 1,007 1,358 
Rapid and Molecular393 362 755 460 355 815 
Cancer Diagnostics890 29 919 — — — 
Total1,660 1,432 3,092 811 1,362 2,173 
Medical Devices —    
Rhythm Management377 366 743 340 333 673 
Electrophysiology420 441 861 362 393 755 
Heart Failure313 88 401 282 86 368 
Vascular294 509 803 283 474 757 
Structural Heart225 372 597 249 332 581 
Neuromodulation189 71 260 193 61 254 
Diabetes Care 862 1,326 2,188 794 1,187 1,981 
Total2,680 3,173 5,853 2,503 2,866 5,369 
Other5 — 5 5 — 5 
Total$5,216 $7,377 $12,593 $4,276 $6,866 $11,142 
Six Months Ended June 30, 2026Six Months Ended June 30, 2025
(in millions)U.S.Int’lTotalU.S.Int’lTotal
Established Pharmaceutical Products —
Key Emerging Markets$— $2,253 $2,253 $— $2,024 $2,024 
Other— 672 672 — 619 619 
Total— 2,925 2,925 — 2,643 2,643 
Nutritional Products —
Pediatric Nutritionals1,036 942 1,978 1,175 920 2,095 
Adult Nutritionals679 1,504 2,183 737 1,526 2,263 
Total1,715 2,446 4,161 1,912 2,446 4,358 
Diagnostic Products —
Core Laboratory724 1,966 2,690 683 1,852 2,535 
Rapid and Molecular858 709 1,567 999 693 1,692 
Cancer Diagnostics983 32 1,015 — — — 
Total2,565 2,707 5,272 1,682 2,545 4,227 
Medical Devices —
Rhythm Management716 711 1,427 644 614 1,258 
Electrophysiology798 851 1,649 695 735 1,430 
Heart Failure605 185 790 544 163 707 
Vascular585 995 1,580 551 916 1,467 
Structural Heart449 726 1,175 497 615 1,112 
Neuromodulation366 137 503 369 113 482 
Diabetes Care 1,684 2,584 4,268 1,542 2,266 3,808 
Total5,203 6,189 11,392 4,842 5,422 10,264 
Other7 — 7 8 — 8 
Total$9,490 $14,267 $23,757 $8,444 $13,056 $21,500 
___________________________________
Notes:
Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the second quarter of 2025 and $101 million of sales in the first six months of 2025 were moved from Structural Heart to Electrophysiology.
Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business.
On March 23, 2026, Abbott completed the acquisition of Exact Sciences Corporation (Exact Sciences). Following the acquisition, the sales of Exact Sciences are presented as Cancer Diagnostics.
Remaining Performance Obligations

As of June 30, 2026, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was $6.2 billion in the Diagnostic Products segment, $455 million in the Medical Devices segment, and $243 million in the Established Pharmaceuticals Products segment. Abbott expects to recognize revenue on approximately 52 percent of these remaining performance obligations over the next 24 months, approximately 18 percent over the subsequent 12 months, and the remainder thereafter.

These performance obligations primarily reflect the future sale of products in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in FASB Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.

Other Contract Assets and Liabilities

Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and the end of the period, as well as the changes in the balance, were not significant.

Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise primarily in the Medical Devices segment when payment is received upfront for various multi-period extended service arrangements.

Changes in the contract liabilities during the period are as follows:

(in millions)
Contract Liabilities:
Balance at December 31, 2025$633 
Unearned revenue from cash received during the period271 
Revenue recognized related to contract liability balance(244)
Balance at June 30, 2026$660